65,437 trials
Neuralgia · Spinal Cord Injuries
Primary: Duration Adjusted Average Change (DAAC) of Mean Pain Score — -1.66; -1.07 score on scale — p=0.0032
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate — 49.06; 0; 49.84; 50.77 ng/ml
Allergic Conjunctivitis
Primary: Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge, 16 Hours After Treatment Instillation. — 0.69; 2.27 units on a scale
Labor Pain · Pregnancy
Primary: Delivered by Cesarean Section — 134; 126 participants — p=0.65
Epilepsy · Neuropathic Pain · Fibromyalgia
Primary: Percentage of Participants Achieving 28 Days Seizure Free Period in Intent-to Treat (ITT) Population — 66.30 Percentage of participants
Lymphoma, Follicular
Primary: Number of Participants With Objective Response (OR) — 0; 1; 2; 0 participants
Hepatitis C
Primary: Number of Participants With Less Than 100 Hepatitis C Virus RNA Copies/mL — 7; 7 Participants — p=<0.05
Androgenetic Alopecia
Primary: Increase in Hair Follicles Present — 16.9; 18.3 Hair follicles — p=0.023
Pain
Primary: AUC-VAS With Movement (Post-operative Period, Hour-6-28) — 1326.1; 1005.0 AUC-VAS pain v. time (mm*hr)
Astigmatism
Primary: Prescription Equivalence — 34 participants
Hypogonadism
Primary: Percentage of Subjects on Testosterone Treatment Achieving Target Range for Testosterone Cav (Time-averaged Concentration Over the Dosing Interval of 24 Hours) on Day…
Refractive Error · Myopia
Primary: Papillary Conjunctivitis — 1.22; 1.04 units on a scale
Heart Failure, Congestive
Primary: Occurrence of Heart Failure (HF) Related Adverse Event (AE) — 29; 50 participants — p=0.0119
Lymphoma
Primary: Overall Survival at 100 Days Post Transplant (Number of Surviving Participants) — 16; 19 participants
Cannulation
Primary: First Attempt Success Rate of Cannulation — 54; 54; 18; 20 Participants — p=.851